Daniel Craig Nelson

Rockville, MD, United States of America

Daniel Craig Nelson

This inventor holds 13 USPTO granted patents and 1 published patent application, primarily in Bacteriophage Research. Top assignees: The Rockefeller University, University System of Maryland, Government of the United States of America, as Represented by the Secretary of Commerce. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Craig Nelson. Retrieved from https://idiyas.com/inventor/daniel-craig-nelson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 69.2

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 71(Granted Patents)


Location History:

  • New York, NY (US) (2003 - 2013)
  • Rockville, MD (US) (2013 - 2024)

Company Filing History:


Years Active: 2003-2026

Loading Chart...
Areas of Expertise:
Bacteriophage
Endolysins
Bacteriolytic Enzymes
Pharmaceutical Compositions
Nucleic Acids
Polypeptides
Chimeric Enzymes
Amidolytic Activity
Infection Treatment
C1 Bacteriophage
Lytic Systems
13 patents (USPTO):Explore Patents

Title: Innovations of Daniel Craig Nelson

Introduction

Daniel Craig Nelson is a prominent inventor based in Rockville, MD (US). He holds a total of 12 patents, showcasing his significant contributions to the field of biotechnology and pharmaceuticals. His work primarily focuses on developing innovative methods and compositions to combat bacterial diseases and infections.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Endolysins Active Against Bacteria, Pharmaceutical Compositions, and Methods Relating Thereto." This invention relates to methods of treating or preventing bacterial diseases or infections through the use of antibacterial compositions and surfaces. It includes an isolated polypeptide comprising an enzymatically active domain (EAD) of a bacteriophage endolysin. Another notable patent is the "Di-Enzymatic Chimeric Endolysin," which features a primary enzymatic active domain that cleaves glycosidic, peptide, or amide bonds. This invention also includes a secondary enzymatic active domain that synergistically enhances the cleavage of peptidoglycan, demonstrating a sophisticated approach to bacterial treatment.

Career Highlights

Daniel Craig Nelson has had a distinguished career, working with esteemed institutions such as The Rockefeller University and the University System of Maryland. His research has significantly advanced the understanding of antibacterial mechanisms and has the potential to lead to new therapeutic options for bacterial infections.

Collaborations

Throughout his career, Nelson has collaborated with notable scientists, including Vincent A. Fischetti and Raymond Schuch. These collaborations have contributed to the development of innovative solutions in the field of microbiology.

Conclusion

Daniel Craig Nelson's contributions to the field of biotechnology through his patents and research are invaluable. His innovative approaches to combating bacterial infections highlight the importance of continued research and development in this critical area of health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…